About Agenovir
Agenovir is a company based in San Francisco (United States) founded in 2014 was acquired by Vir Biotechnology in May 2018. Agenovir has raised $10.6 million across 2 funding rounds from investors including Lightspeed Venture Partners, Vir Biotechnology and HHS. Agenovir operates in a competitive market with competitors including Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Agenovir Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.6 M (USD)
in 2 rounds
-
Latest Funding Round
$10.6 M (USD), Series A
May 17, 2016
-
Investors
Lightspeed Venture Partners
& 4 more
-
Employee Count
Not available
-
Acquired by
Vir Biotechnology
(May 10, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Agenovir
Unlock access to complete
Unlock access to complete
Leadership Team
45 people
Operations Team
11 people
Software Development Team
8 people
Senior Team
8 people
Finance and Accounting
6 people
Product Management Team
3 people
Human Resources and Administration
2 people
Sales and Marketing
2 people
Unlock access to complete
Funding Insights of Agenovir
Agenovir has successfully raised a total of $10.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $10.6 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Agenovir
Agenovir has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Vir Biotechnology and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners.
|
Locked | Locked | Locked | |
|
Therapies for cancer and inflammatory diseases are developed.
|
Locked | Locked | Locked |
Investor details for Agenovir
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Agenovir
Investment portfolio details for Agenovir
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Agenovir
Detailed financials for Agenovir
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Agenovir Comparisons
Peer comparison for Agenovir
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Agenovir
Agenovir operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Alnylam, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
Detailed competitors of Agenovir
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Agenovir
Complete news archive for Agenovir
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Agenovir
Agenovir was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Agenovir is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Agenovir is a funded company, having raised a total of $10.6M across 2 funding rounds to date.
Agenovir was established in 2014 in San Francisco, United States, within the biotechnology sector. Focus is placed on creating antiviral therapeutics targeting infectious diseases tied to latent or persistent viral reservoirs. CRISPR-Cas9 and other nucleases are employed to target and remove pathogenic viral DNA inside cells. Development efforts center on innovative gene-editing methods to address viral persistence.
Agenovir's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Agenovir has 5 investors. Key investors include Lightspeed Venture Partners, Vir Biotechnology, HHS, Celgene, and DCVC.